Anti-CASPR2 encephalitis in a liver posttransplant patient receiving immune-suppression and lenvatinib: a case report and literature review

Neurol Sci. 2023 Mar;44(3):1069-1072. doi: 10.1007/s10072-022-06560-4. Epub 2022 Dec 22.

Abstract

It has been assumed that patients with strict immunosuppressive treatment after solid organ transplantation have only marginal risk in developing autoimmune encephalitis. We reported a woman in her late 40 s who presented with generalized convulsions and loss of consciousness. After detailed history review, neuropsychological tests, metagenomic next-generation sequencing of serum and cerebrospinal fluid (CSF), magnetic resonance imaging (MRI) brain, and electroencephalogram, she was diagnosed as anti-CASPR2 encephalitis based on the positive anti-CASPR2 auto-antibody in serum and CSF. The patient underwent liver transplantation and has taken lenvatinib for 2 months, in addition to tacrolimus, mycophenotale mofetil, and entecavir administered for half a year. This case was the first report of anti-CASPR2 encephalitis in post-organ transplantation patients. Together with the reports of other encephalitis cases in organ transplantation, it warns the possibility of developing immune-oriented encephalitis in patients undergoing immunosuppression, especially in combination with other treatments of immunomodulatory activity.

Keywords: Autoimmune encephalitis; CASPR2; Immune-suppression; Seizure; Transplantation.

Publication types

  • Review
  • Case Reports

MeSH terms

  • Autoantibodies*
  • Encephalitis* / drug therapy
  • Encephalitis* / etiology
  • Female
  • Humans
  • Immunosuppression Therapy / adverse effects
  • Liver

Substances

  • Autoantibodies
  • lenvatinib
  • anti-CASPR2 autoantibody